| 他莫昔芬诱导非酒精性脂肪肝的机制研究进展 |
| |
| 引用本文： | 陈 曦,凌嘉伟,丁嘉欣,江振洲,张陆勇.他莫昔芬诱导非酒精性脂肪肝的机制研究进展[J].金属学报,2018,23(6):715-720. |
| |
| 作者姓名： | 陈 曦 凌嘉伟 丁嘉欣 江振洲 张陆勇 |
| |
| 作者单位： | 1.中国药科大学江苏省新药筛选重点实验室，南京 210009，江苏；;2.广东药科大学药学院新药筛选与药效学评价中心，广州 510006，广东；;3.药物质量与安全预警教育部重点实验室（中国药科大学），南京 210009，江苏 |
| |
| 基金项目： | 国家自然科学基金面上项目（81773827）；公益性行业科研专项（201507004-002）；国家重大新药创制专项（2015ZX09501004-002-004）；国家自然科学基金重大国际（地区）合作研究项目（81320108029） |
| |
| 摘 要： | 选择性雌激素受体拮抗剂他莫昔芬目前在临床上乳腺癌术后内分泌治疗的应用中最为广泛，然而，越来越多的证据显示他莫昔芬可大大提高乳腺癌患者非酒精性脂肪肝的发病风险。目前关于他莫昔芬造成肝脏脂毒性的研究并不详尽，其造成非酒精性脂肪肝的具体机制仍不明确，本文对他莫昔芬诱导非酒精性脂肪肝这一现象及其机制研究进展进行综述，为后续深入探索其机制及研发治疗药物提供参考。
|
| 关 键 词： | 他莫昔芬 辅助内分泌治疗 非酒精性脂肪肝 发病机制 |
| 收稿时间： | 2018-03-19 |
| 修稿时间： | 2018-04-18 |
Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen |
| |
| CHEN Xi,LING Jiawei,DING Jiaxin,JIANG Zhenzhou,ZHANG Luyong.Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen[J].Acta Metallurgica Sinica,2018,23(6):715-720. |
| |
| Authors: | CHEN Xi LING Jiawei DING Jiaxin JIANG Zhenzhou ZHANG Luyong |
| |
| Affiliation: | 1. Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, Jiangsu, China;2.Center for Drug Screening and Pharmacodynamics Evaluation, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China;3.Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing 210009, Jiangsu, China |
| |
| Abstract: | Tamoxifen, a selective estrogen receptor antagonist, is most widely used for endocrine therapy for breast cancer. However, mounting evidence suggests that tamoxifen treatment can significantly improve the risk of nonalcoholic fatty liver disease (NAFLD) in breast cancer patients. At present, there is no enough research on hepatic lipotoxicity caused by tamoxifen, the exact mechanism of it is still unknown. In this paper, we reviewed the phenomenon and mechanism of tamoxifen induced nonalcoholic fatty liver disease, providing references for further mechanism research and therapeutic drugs development. |
| |
| Keywords: | tamoxifen endocrine therapy nonalcoholic fatty liver disease pathogenesis |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
|
